DV
Dividend Vision

CDT — Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc. (CDT)

Total return is -100.0% over the past 4.4 years, 180.4 points behind SPY at 80.4%. Its deepest 1-year drawdown was 99.9%.

CDT Equity Inc. is a data-driven biopharmaceutical company that identifies, enhances, and monetizes therapeutic assets, with a clinical pipeline including glucokinase activator AZD1656 in Phase II trials for autoimmune disorders, AZD5658 in Phase I development for Type 2 Diabetes, and AZD5904 for male infertility, along with treatments across inflammatory disorders, oncology, dermatology, and rare diseases. The company does not currently distribute to shareholders. This security appeals primarily to growth-oriented investors with risk tolerance for early-stage biopharmaceutical development, as the company is pre-revenue and focused on advancing its pipeline candidates through clinical trials.

CDT key facts

Asset type
Stock
Asset class
Equity
Inception date
03/28/2022
Last close
$2.92
Market cap
$197,779
Average volume
28200.0
Beta
1.457
Payout ratio
0.0
Forward P/E
0.0
EPS
$-81.60